Robert C. Doebele, MD, PhD

Robert C. Doebele, MD, PhD, an associate professor in the Division of Medical Oncology at the School of Medicine, University of Colorado, shares his thoughts on what the next steps are for entrectinib (Rozlytrek) in patients with

-positive nonsmall cell lung cancer (NSCLC). In August of 2019, the FDA granted approval to this agent as treatment of patients with metastatic NSCLC who are

Understanding the mechanisms of resistance to entrectinib is an important next step, says Doebele. Next-generation drugs are being evaluated following failure with entrectinib, such as agents like repotrectinib (TPX-0005). However, understanding the types of resistance we see with entrectinib may further help us understand which drug should follow entrectinib. Doebele says that having new therapies for patients who fail first-line therapies is 1 of the goals in among oncologists who specialize in lung cancer.

In August 2019, entrectinib also received an accelerated approval from the FDA for the treatment of adult and adolescent patients with solid tumors harboring an

gene fusion who have no alternative therapies available. For more information on these approvals of entrectinib:&nbsp;

https://www.targetedonc.com/news/fda-approves-entrectinib-for-ros1-nsclc-and-ntrk-solid-tumors

Videos

Robert C. Doebele, MD, PhD, shares his thoughts on what the next steps are for entrectinib in patients with&nbsp;<em>ROS1</em>-positive non&ndash;small cell lung cancer. In August of 2019, the FDA granted approval to this agent as treatment of patients with metastatic NSCLC who are&nbsp;<em>ROS1</em>-positive.

Evaluating Next Steps for Entrectinib in ROS1-Positive NSCLC

Robert C. Doebele, MD, PhD, associate professor at the University of Colorado, discusses resistance in patients with

According to Doebele, studies are still early in this patient population, but 2 have been published so far. Both showed that

mutations can occur, but data published from the University of Colorado, showed a rate of about 10%, while the study from Massachusetts General Hospital showed about 50%.

While these results are very different, both studies were relatively small. Doebele believes it might be around 30%, as with

lung cancer. Drugs need to be developed to overcome kinase domain mutations in ROS1, but first investigators must identify what those resistance mutations are and the other type of resistance mechanisms in&nbsp;

Robert C. Doebele, MD, PhD, discusses resistance in patients with ROS1-positive lung cancer.

Investigating Resistance in ROS1+ Lung Cancer

Robert C. Doebele, MD, PhD, associate professor in the Division of Medical Oncology at the University of Colorado, discusses the significance of brain metastases in patients with nonsmall cell lung cancer (NCSLC).

The current standard of care for patients with NCSLC is crizotinib (Xalkori), but this treatment does not have a high response rate and does not allow for good control of brain metastases. Entrectinib (RXDX-101) is currently being tested in clinical trials and has proven to have better control on brain metastases.

Robert C. Doebele, MD, PhD, associate professor in the Division of Medical Oncology at the University of Colorado, discusses the significance of brain metastases in patients with non&ndash;small cell lung cancer.&nbsp;

The Significance of Brain Metastases in Non-Small Cell Lung Cancer

Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses the significance of the results of a trial exploring entrectinib in patients with&nbsp;ROS1-positive non&ndash;small cell lung cancer (NSCLC).

Robert C. Doebele, MD, PhD | Authors

Articles

Evaluating Next Steps for Entrectinib in ROS1-Positive NSCLC

Investigating Resistance in ROS1+ Lung Cancer

The Significance of Brain Metastases in Non-Small Cell Lung Cancer

The Significance of Results for Entrectinib in ROS1+ NSCLC